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HCV repliconA replication requires viral nonstructural proteins as well as cellular factors.
Recently, a cellular protein, synaptotagmin-binding, cytoplasmic RNA-interacting protein (SYNCRIP), also
known as NSAP1, was found to bind HCV RNA and enhance HCV IRES-dependent translation. We investigate
whether this protein is also involved in the HCV RNA replication. We found that SYNCRIP was associated with
detergent-resistant membrane fractions and colocalized with newly-synthesized HCV RNA. Knock-down of
SYNCRIP by siRNA signiﬁcantly decreased the amount of HCV RNA in the cells containing a subgenomic
replicon or a full-length viral RNA. Lastly, an in vitro replication assay after immunodepletion of SYNCRIP
showed that SYNCRIP was directly involved in HCV RNA replication. These ﬁndings indicate that SYNCRIP has
dual functions, participating in both RNA replication and translation in HCV life cycle.
© 2009 Elsevier Inc. All rights reserved.IntroductionHepatitis C virus (HCV) infection is a leading cause of chronic
hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV is an
enveloped RNA virus with a positive-stranded RNA of 9.7 kb in length
(Reed and Rice, 2000). It encodes a large polyprotein, which is then
processed into structural proteins (C, E1, and E2) and nonstructural
(NS) proteins, the latter of which participate in viral replication.
Besides the viral NS proteins, several host factors, including the
human homologue of the 33-kDa vesicle-associated membrane
protein-associated protein (hVAP-33) (Gao et al., 2004; Hamamoto
et al., 2005), polypyrimidine-tract-binding protein (PTB) (Aizaki et al.,
2006; Chang and Luo, 2006; Domitrovich et al., 2005), La antigen
(Domitrovich et al., 2005) and host geranylgeranylated proteins and
fatty acids (Kapadia andChisari, 2005) havebeen shown to be involved
in some steps of HCV replication cycle. Some of these host factors, such
as PTB and La autoantigen, were initially found to regulate HCV protein
translations (Ali and Siddiqui,1997; Ito and Lai,1999) by virtue of their
binding to the 5′ and 3′-untranslated regions (UTR) of HCV RNA. Later
studies showed that some of these host factors also directly regulate
HCV RNA replication either by participating in the formation of the
RNA replication complex (e.g., VAP-33) (Gao et al., 2004) or by bindingy, Academia Sinica, Taipei 115,
Lai).
ll rights reserved.to the viral RNA (e.g., La, PTB) (Ali and Siddiqui, 1995; Chang and Luo,
2006). A recent study showed that another host protein, synaptotag-
min-binding, cytoplasmic RNA-interacting protein (SYNCRIP), also
named NS-1-associated protein (NSAP1), binds to the N-terminal of
the core protein-coding region of HCV RNA and enhances HCV Internal
Ribosomal Entry Site (IRES)-dependent translation (Kim et al., 2004).
SYNCRIP is a member of cellular heterogeneous nuclear ribonucleo-
protein (hnRNP) family, to which PTB also belongs. hnRNPs are well-
known for their abilities to bind to cellularproteins andRNAs to facilitate
many biological processes. Interestingly, SYNCRIP has previously been
shown to be involved not only in cellular processes but also in mouse
hepatitis virus (MHV) RNA replication (Choi et al., 2004b). Since
SYNCRIP binds to HCV RNA at a site close to the 5′-end of the RNA, it is
likely that SYNCRIP may also affect the RNA replication of HCV. If this is
the case, SYNCRIP will have duel functions in both RNA replication and
protein translation, similar to other duel-purpose hnRNPs, such as PTB.
Our goal in this study is to investigate whether SYNCRIP is involved in
HCV RNA replication in addition to its role in translation.
Results
SYNCRIP relocalized to detergent-resistant membrane fraction in HCV
replicon cells
It has been shown that HCV RNA replication occurs in detergent-
resistantmembrane (DRM) fractions (Ali et al., 2002; El-Hage and Luo,
Fig. 1.Membrane ﬂotation assay showed relocalization of SYNCRIP to DRM in HCV replicon cells. Cell lysates were prepared from HCV replicon (HuhN1b) or Huh7 cells by passing
through a 25-gauge needle 20 times. Nuclei and unbroken cells were removed by centrifugation at 1000 ×g for 5 min in microcentrifuge at 4 °C. The supernatants treated with or
without 1% TX-100 at 4 °C for 30 minwere fractionated by discontinuous sucrose gradient centrifugation. Fractions were collected from the top, numbered from 1 to 9. Each fraction
was concentrated by Centricon YM-30 (Millipore, MA) and immunoblotted by rabbit anti-SYNCRIP antibody or mouse anti-Calnexin antibody, respectively. SYNCRIP was found in
both membrane and soluble fractions in the untreated Huh7 and HuhN1b cells, whereas in the HuhN1b cells, some SYNCRIP was localized to the DRM fractions. This phenomenon is
not seen in the Calnexin proﬁle.
250 H.M. Liu et al. / Virology 386 (2009) 249–2562003; Mizutani et al., 2000). The nonstructural proteins of HCV are
associated with the DRM structures containing Caveolin-2, strongly
suggesting that the viral replication complex has properties of lipid
rafts (Gao et al., 2004; Mizutani et al., 2000). To determine whether
SYNCRIP is in the RNA replication complex, we performed membrane
ﬂotation analysis of HCV replicon cells, followed by immunoblotting
with anti-SYNCRIP antibody to examine the possible presence of
SYNCRIP in the detergent-resistant membrane fractions, where theFig. 2. SYNCRIP colocalizationwith de novo-synthesized HCV RNA in a HCV replicon cell. peGF
days after transfection, Huh7 or HCV replicon cells were labeled with BrUTP for 15 min aft
incorporation in Huh7 cells (left two panels), but not in HuhN1b replicon cells, where BrU l
performed with sheep polyclonal antibody against BrdU (anti-BrdU) followed by Rhodamin
cells are shown, representing two different distribution patterns of BrUTP, as shown previoHCV replication complexes reside.We found that SYNCRIPwas present
mostly in the cytosolic fractions (fractions 6–9, Fig.1) in bothHuh7 and
HuhN1b cells, but a small fraction was associated with the membrane
(fractions 2–4, Fig. 1). After treatment with Triton X-100 at 4 °C, some
SYNCRIP was still associated with the membrane in HuhN1b cells; in
contrast, almost all of SYNCRIP was solubilized in Huh7 cells. Longer
exposure of immunoblottingwas performed, and SYNCRIPwas still not
found in the DRM fractions of TX-100 treated Huh7 cells. As a control,P-SYNCRIP was transfected into Huh7 or HCV replicon (HuhN1b) cells by Fugene 6. Two
er one-hour treatment with Actinomycin D. Actinomycin D treatment inhibited BrUTP
abel was detected in the cytoplasm (right 6 panels). Immunoﬂuorescence staining was
e-conjugated anti-sheep antibody (Jackson ImmunoResearch). Two different HuhN1b
usly (Mizutani et al., 2000).
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exclusively in the membrane fractions (fraction 2–3) in the absence
of detergent treatment in both Huh7 andHuhN1b cells (Fig.1, panel 3).
After the cells were treated with cold detergent, Calnexin was
redistributed entirely to the soluble fractions, indicating that Calnexin
was associated with detergent-soluble membrane, which is a known
characteristic of unmodiﬁed ER. These data suggested that SYNCRIP is
predominantly a cytoplasmic protein, but is relocalized to the DRM
fractions (fraction 2–3 after TX-100 treatment) in theHuhN1b replicon
cells. The relocalization of SYNCRIP protein, but not Calnexin, to the
DRM fraction in the HuhN1b replicon cell indicated that SYNCRIP may
be speciﬁcally recruited by HCV RNA to the replication complexes,
since SYNCRIP binds to HCV RNA (Kim et al., 2004).
SYNCRIP colocalized with de novo synthesized RNA in HCV replicon cells
Previous studies on HCV replicon cells have shown that the newly
synthesized HCV RNA and the viral nonstructural proteins colocalizedFig. 3. SYNCRIP knock-down by siRNA in HCV replicon cells. The siRNAs against SYNCRIP (siR
cells. Two days after the ﬁrst transfection, each siRNA was re-transfected into the same cells
monitored by immunoblotting (A), and HCV RNA levels were detected by realtime RT-PCR (
replicon cells. (D), intracellular replicon RNA level was examined by realtime RT-PCR. R1d an
siRNA; N, nonspeciﬁc siRNA.with each other on the distinct speckle-like structure in the cytoplasm
of the replicon cells (Gosert et al., 2003; Mizutani et al., 2000). To
examine whether SYNCRIP is associated with HCV RNA synthesis in
the speckle structures, BrUTP labeling was performed in HCV replicon
cells transfected with peGFP-SYNCRIP (a gift from Dr. Mizutani, The
University of Tokyo). Brieﬂy, 2 days after transfection of peGFP-
SYNCRIP, BrUTP was transfected into actinomycin D-pretreated cells
(Kanestrom et al., 1998). Immunoﬂuorescence staining with sheep
anti-BrdU polyclonal antibody (Biodesign, ME) was then performed
(Kanestrom et al., 1998). Under this condition, all of the BrU-label
represents HCV RNA since the cellular transcription is inhibited by
actinomycin D treatment. The BrU-labeled RNA was present either in
distinct speckle-like structures or in large spherical particles in the
cytoplasm of the replicon cell (Fig. 2), consistent with our previous
report (Mizutani et al., 2000). These two patterns probably represent
two different states of viral RNA synthesis. No BrU-labeled RNA was
found in Huh7 cells without an HCV replicon. SYNCRIP was also
localized in the cytoplasm in Huh7 cells without HCV replicon, but in aNA 1 and 3) (Choi et al., 2004b) or nonspeciﬁc siRNAwere transfected into HCV replicon
to ensure complete knock-down of SYNCRIP. Endogenous SYNCRIP protein levels were
B). (C), immunoblotting of SYNCRIP and NS3 expression in SYNCRIP siRNA knock-down
d R2d, one or 2 days after re-transfection of siRNA. siRNA 1 and 3, two different clones of
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found that eGFP-SYNCRIP was partially colocalized with BrU-labeled
RNA in the replicon cells (Fig. 2), indicating that only a portion of
SYNCRIP was recruited to the HCV RNA replication site. This ﬁnding is
consistent with the fractionation proﬁle, which showed that SYNCRIP
is primarily a cytosolic protein and that only a portion of SYNCRIP is
relocalized to the DRM fractions in the replicon cells (Fig. 1). This
phenomenon was also observed with PTB in the replicon cell (Aizaki
et al., 2006), in which only a small portion of PTB was relocalized to
the cytoplasm, whereas the majority remained in the nucleus. These
results suggested that a portion of SYNCRIP is localized to the HCV
replication complex, implying that SYNCRIP is involved in HCV RNA
replication.
In vivo knock-down of SYNCRIP suppressed HCV replication
To determine the biological role of SYNCRIP in HCV RNA
replication, we monitored HCV RNA levels in HCV replicon cells in
which the endogenous SYNCRIP was knocked down with the RNA
interference method (Aizaki et al., 2006; Wagner and Garcia-Blanco,
2002). HuhHyg replicon cells were transfected with either SYNCRIP-
speciﬁc (siRNA 1 and 3) (Choi et al., 2004b) or nonspeciﬁc (NS) siRNA.
Protein analysis by immunoblotting was performed with rabbit
polyclonal anti-SYNCRIP antibody, and HCV RNA level was monitored
by using Taqman quantitative realtime RT-PCR (Gao et al., 2004). The
cells transfected with SYNCRIP siRNA showed a signiﬁcant reduction
of the endogenous SYNCRIP by day 2 post-transfection (Fig. 3A). One
day after re-transfectionwith the same siRNAs respectively, almost no
endogenous SYNCRIP could be detected (R1d, Fig. 3A). Correspon-
dingly, SYNCRIP siRNA-transfected HCV replicon cells showed a
70–80% reduction of HCV RNA by day 2 after re-transfection with
the siRNA as compared to that in the cells transfected with the
nonspeciﬁc siRNA (R2d, Fig. 3B). The lag time of more than 1 day
between the drop of SYNCRIP and that of HCV RNA was probably due
to the relative stability of the HCV RNA.
HuhN1b replicon cells were also used to conﬁrm the result
obtained using HuhHyg replicon cells. SYNCRIP knock-down was
achieved by siRNA transfection, and the viral protein and RNA levels
were examined in a time-course study. While the nonspeciﬁc siRNA
did not signiﬁcantly affect SYNCRIP expression, the expression levels
of SYNCRIP were dramatically decreased after the transfection of
speciﬁc siRNA against SYNCRIP (siRNA 3) (Fig. 3C). Correspondingly, a
50% decrease in intracellular replicon RNAwere detected from day 2 p.
t. (Fig. 3D). The decrease in NS3 expressionwas also detected in siRNA
3-transfected cells; however, the viral proteinwas not decreased until
4 days after siRNA transfection (Fig. 3C). These results suggest that
SYNCRIP affects both HCV RNA translation and RNA replication, but
exerts these effects through different mechanisms.
It has been reported that SYNCRIP interacts with HCV RNA
fragment spanning nt 342 to 374, corresponding to the N-terminus
of the core protein-coding region (Kim et al., 2004). Since this region
is immediately downstream to the neomycin-phosphotransferase
gene in the HCV replicon, it is possible that the observed involvement
of SYNCRIP in the HuhN1b replicon cells was due to the possible
effects of SYNCRIP on the expression of phosphotransferase. To rule
out this possibility, we further examined the role of SYNCRIP in the
replication of HCV full-length RNA (pHCV-1b-hyb) without the
neomycin phosphotransferase gene. Huh7 cells were ﬁrst transfected
and re-transfected with SYNCRIP-speciﬁc siRNA to knock-down the
endogenous SYNCRIP protein; 1 day after re-transfection of siRNA, the
cells were transfected with the replication-competent full-length HCV
RNA (HCV-1b). The SYNCRIP expressions and NS3 levels in siRNA-
transfected cells were examined by immunoblotting. SYNCRIP
expression was signiﬁcantly decreased in cells transfected with
speciﬁc siRNA (siRNA 1 or 3) (Fig. 4A). Correspondingly, NS3
expression was also affected by the speciﬁc SYNCRIP siRNA; insiRNA 1- and siRNA 3-transfected cells, NS3 was detected in the ﬁrst
2 days post-transfection of HCV full-length RNA, but became
undetectable thereafter, whereas in the nonspeciﬁc siRNA-transfected
cells, NS3 was detected up to 4 days after HCV RNA transfection
(Fig. 4A). Total intracellular HCV RNAwas determined at various days
by quantitative realtime RT-PCR. In the cells transfected with the
nonspeciﬁc siRNA, HCV RNA titer gradually increased during the ﬁrst
72 h post-transfection, in agreement with the published report (Choi
et al., 2004a) (Fig. 4B). In contrast, in the cells transfected with the
SYNCRIP-speciﬁc siRNA, HCV RNA titer decreased steadily over the
same period of time (Fig. 4B). Although NS3 was detected in the ﬁrst
2 days after HCV RNA transfection in SYNCRIP-knocked down cells
(Fig. 4A), there was no sign of HCV replication (Fig. 4B). The
intracellular HCV RNA level normalized by NS3 expression level was
shown in Fig. 4C. Regardless the NS3 expression detected in SYNCRIP
knock-down cells, HCV RNA titer constantly decreased after full-
length HCV RNA transfection. There was a slight increase in
intracellular HCV RNA level at day 5 post-transfection of HCV full-
length RNA, probably due to the increase in SYNCRIP protein level.
This result suggested that endogenous SYNCRIP is directly involved in
HCV replication, but not through the suppression of the expression of
neomycin phosphotransferase gene. These results combined indicate
that SYNCRIP is involved in HCV replication by affecting either HCV
RNA replication or translation, or both.
SYNCRIP inhibited HCV RNA replication in vitro
The siRNA knock-down approaches showed that once SYNCRIP
protein level was decreased, the HCV RNA titer would be correspon-
dingly decreased. Since SYNCRIP has been shown to be directly
involved in HCV translation (Kim et al., 2004), the inhibition of HCV
RNA replication in SYNCRIP-knock-down cells may have resulted from
the indirect effect of inhibition of translation; namely, the viral NS
protein synthesis was inhibited, and thereby viral RNA synthesis was
decreased.
To distinguish the effect of SYNCRIP on RNA replication from that
on translation, we designed experiments to separate viral RNA
replication from viral translation. We employed an in vitro replication
assay using crude membrane fractions of the HCV subgenomic
replicon cells (Ali et al., 2002; Gao et al., 2004), after the endogenous
SYNCRIP had been knocked down by the siRNA approach. We also
performed in vitro RNA replication assay after SYNCRIP was depleted
with the anti-SYNCRIP antibody from the cell lysates.
Immunoblotting showed that the amount of SYNCRIP in the
HuhN1b replicon cells was substantially reduced by the speciﬁc siRNA
treatment for 2 days (Fig. 5A). At this time, the amount of NS5A was
only partially reduced. Cell lysates from siRNA-transfected replicon
cells were treated with TX-100 at 4 °C for 30 min and fractionated by
sucrose gradient centrifugation to isolate DRM fraction (Aizaki et al.,
2006; Ali et al., 2002). The DRM fractions from these cell lysates were
then used for in vitro replication assay. The HCV RNA synthesis was
detected as single band of 32P-labeled RNA. The result showed that
there was no detectable RNA replication activity at all in the DRM
fractions from the SYNCRIP siRNA-transfected replicon cells when
compared with those from the non-transfected or nonspeciﬁc siRNA-
transfected replicon cells (Fig. 5A). Since there was still a signiﬁcant
amount of NS5A remaining in the siRNA-transfected cells, the total
lack of the in vitro replication activity in SYNCRIP knocked-down
replicon cells suggested a direct role of SYNCRIP in HCV RNA
replication.
We further performed an immunodepletion experiment to remove
SYNCRIP form the DRM fraction and assessed the effects on HCV RNA
replication in vitro. For immunodepletion, the DRM fractions from
replicon cell lysates were incubated with a rabbit anti-SYNCRIP
polyclonal antibody to deplete the endogenous SYNCRIP from the
lysate. After incubation, samples were used for cell-free synthesis of
Fig. 4. Deﬁciency of full-length HCV replication in SYNCRIP knock-down Huh7 cells. The siRNAs against SYNCRIP (siRNA 1 and 3) or nonspeciﬁc siRNA were transfected into Huh7
cells twice to knock-down endogenous SYNCRIP level as described in Fig. 3. One day after re-transfection of siRNA, in vitro synthesized full-length HCV-1b-hyb RNAwas transfected to
siRNA-transfected Huh7 cells respectively. (A), immunoblotting of endogenous SYNCRIP after siRNA re-transfection, and NS3 expression levels at various days after HCV RNA
transfection. (B), intracellular HCV RNA levels determined by quantitative RT-PCR, and (C), intracellular HCV RNA levels normalized by NS3 expression levels. Huh7 cells were
transfected with SYNCRIP-speciﬁc or nonspeciﬁc siRNA as in (A). One day after siRNA transfection, the replication-competent full-length HCV RNAwas transfected into the cells, and
HCV RNA levels were detected by realtime RT-PCR on different days after the HCV RNA transfection. The relative amounts of HCV RNA are expressed as in Fig. 3B.
253H.M. Liu et al. / Virology 386 (2009) 249–256HCV RNA. The results showed that the treatment with anti-SYNCRIP
antibody inhibited the replication activity in an antibody concentra-
tion-dependent manner, whereas a control anti-Ig antibody did not
inhibit any activity at the same or an even higher antibody concen-tration (Fig. 5B and data not shown). As a control, anti-VAP33 (VAP-A)
antibody also inhibited HCV RNA replication, similar to the pre-
vious result (Hamamoto et al., 2005), whereas anti-Calnexin antibody
did not.
Fig. 5. siRNA-knock-down or immunodepletion of SYNCRIP inhibited HCV replication
activity in in vitro replication assay. (A) SYNCRIP was knocked down by transfection two
times with speciﬁc siRNA in HCV replicon cells as in Fig. 3. SYNCRIP, NS5A and GAPDH
protein expression were determined by immunoblotting. Cell-free RNA replication
assays using the DRM fraction isolated from the cell lysates, as described in Material and
methods, were performed. 32P-CTP-labeled HCV RNA product was detected by
autoradiography after separation by agarose gel electrophoresis. NC, nonspeciﬁc
siRNA control; SYNCRIP, SYNCRIP-speciﬁc siRNA; No, no siRNA transfection. (B) Partially
puriﬁed lysates of HCV replicon cells were incubated with anti-IgG, anti-SYNCRIP, anti-
VAP-A (VAP-33), or anti-Calnexin antibodies. Then samples were incubated with
α-32P-CTP in a cell-free RNA-dependent RNA polymerase assay. The RNA product was
separated by formaldehyde agarose gels and identiﬁed by autoradiography.
254 H.M. Liu et al. / Virology 386 (2009) 249–256These results combined suggested that SYNCRIP is directly
involved in HCV RNA replication, in addition to its role in regulating
the translation of HCV RNA. Since SYNCRIP is colocalized with the
newly synthesized HCV RNA, it is likely that SYNCRIP is a part of the
HCV RNA replication complex and participates in viral RNA synthesis.
Discussion
Our results show that SYNCRIP can modulate HCV RNA replication.
It has been previously reported that SYNCRIP can also enhance HCV
IRES-dependent translation (Kim et al., 2004). Thus, similar to PTB
and La autoantigen, SYNCRIP has dual functions in HCV life cycle. This
may be a common characteristic of HCV RNA-binding proteins.
In our study, the relocalization of SYNCRIP to the DRM fractions in
HCV replicon cells indicates that SYNCRIP is associated with the RNA
replication complex, which is localized in this membrane fraction. It is
interesting to note that the distribution of Calnexin was slightly
different between the control and the replicon cells; there was some
shift of Calnexin toward the lighter sucrose gradient fractions,
probably cased by the alteration of cellular membrane structures
and the associations of HCV NS proteins to ER membrane structure in
HCV replicon cells (Egger et al., 2000; El-Hage and Luo, 2003; Gosert
et al., 2003; Mottola et al., 2002). Nevertheless, SYNCRIP was clearly
localized in the DRM fraction, whereas Calnexin was not.
The immunodepletion experiments in the current and previous
studies have shown that antibody against PTB, hVAP-A, hVAP-B, and
SYNCRIP can inhibit HCV RNA replication activities speciﬁcally.Previous studies have suggested that the HCV RNA replication
complexes are protein complexes with the newly-synthesized RNA
being contained within (Yang et al., 2004), and that subtilisin protease
treatment could disrupt the replication complexes. However, it was
also reported that the HCV replication complexes were resistant to
proteinase K treatment at room temperature (Aizaki et al., 2004;
Quinkert et al., 2005). The latter study suggested that the HCV
replication complexes were very compact, and therefore the accessi-
bility of immunoglobulin to the speciﬁc protein target in the
replication complex may be limited. However, the ability of these
antibodies to inhibit HCV RNA replication suggested that those
complexes may not be so compact and are accessible by immunoglo-
bulin molecules under these conditions.
The genome of positive-stranded RNA viruses, such as HCV,
poliovirus, and coronavirus, serve as a template for both translation
and the synthesis of negative-strand RNA, the latter of which is, in
turn, the template for synthesizing more positive-strand RNA. The
positive-strand RNA can also be packaged to form new viral particles.
Since the same positive-strand RNA can participate in different steps
of the viral life cycle, the temporal or spatial regulation is very
important. It is likely that the regulation is through RNA–protein
interactions. When in complex with speciﬁc RNPs, the RNA can be
utilized speciﬁcally in different steps. With limited numbers of genes
in the viral genome, the regulation likely requires the participation of
various host factors interacting with the viral RNA or viral proteins.
There are many known host and viral RNA-binding proteins that
can facilitate positive-strand RNA replication, such as Tat protein
binding to the TAR structure in HIV1 RNA (Dingwall et al., 1989;
Wagner and Garcia-Blanco, 2002) and poly(rC)-binding protein
binding to the cloverleaf structure of poliovirus RNA (Blyn et al.,
1996; Gamarnik and Andino, 2000). However, not so many RNA-
binding proteins have been reported to have dual functions in viral
RNA replication and translation. Recently, La and PTB, are found to
regulate both RNA replication and translation of HCV, probably as a
result of their ability to bind to HCV RNA (Aizaki et al., 2006;
Domitrovich et al., 2005). Host factors with dual-regulatory functions
may play important roles in switching the RNA from translation to
replication or replication to translation. For example, PCBP regulates
translation–replication switch in poliovirus life cycle (Back et al.,
2002; Gamarnik and Andino, 1998). It was reported previously that
stem–loop I and II are critical for HCV RNA replication, and stem–loop
II, III, and IV are important for HCV RNA translation (El-Hage and Luo,
2003; Fukushi et al., 2001; Qi et al., 2003). La autoantigen was shown
to bind to loop IV of HCV 5′NTR (Ali and Siddiqui, 1997). Although
there is no evidence that La binds to stem–loop I or II, La can,
nevertheless, regulate HCV replication (Domitrovich et al., 2005).
Similarly, SYNCRIP was reported to bind at nt 342 to 374 (Kim et al.,
2004), a region essential for HCV IRES-driven translation but not HCV
replication. Yet we found signiﬁcant positive regulatory effect of
SYNCRIP in HCV RNA replication. It is possible that the binding of
SYNCRIP to HCV RNA alters the secondary structure of the RNA or
recruits other required factors to facilitate the assembly of the
replication complex.
The mechanism of switching between translation and replication
of HCV RNA is still unclear; conceivably, it may be regulated by these
dual-function proteins which are involved in both replication and
translation. It will be interesting to determine in the future whether
the relative ratio of these proteins may trigger the switch.
Materials and methods
Cells
Huh7 cells were grown at 37 °C in Dulbecco's modiﬁed Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
and nonessential amino acids. Huh7N1b and HuhHyg replicon cells
255H.M. Liu et al. / Virology 386 (2009) 249–256harboring an HCV subgenomic replicon RNA derived from the HCV-N
strain (Guo et al., 2001) were grown in the same medium containing
0.5 mg/ml of G418 or 100 μg/ml of Hygromycin (Mizutani et al.,
2000).
Antibodies and drugs
The primary antibodies used for the analyses in this study were
sheep anti-BrdU polyclonal antibody (BioDesign, ME), mouse anti-
BrdU monoclonal antibody (Caltag, CA), anti-Calnexin monoclonal
antibody (Abcam,MA), anti-GS27monoclonal antibody (Abcam, MA).
Brefeldin A and Nocodazole were purchased from Sigma, and
Actinomycin Dwas from Fisher. The polyclonal anti-SYNCRIP antibody
was generated in rabbits by peptide (amino acid 140 to 152) injection
(Mizutani et al., 2000).
Labeling and immunoﬂuorescence staining of de novo-synthesized
viral RNA
Labeling of de novo-synthesized viral RNA, immunoﬂuorescence
staining and confocal microscopy were modiﬁed from the previously
described procedures (Kanestrom et al., 1998). Brieﬂy, Huh7 or
replicon cells were plated on 8-well chamber slides at a density of
1×104 cells per well. Two days after seeding, cells were incubated
with actinomycin D (10 μg/ml) for 1 h to inhibit cellular RNA
synthesis. Subsequently, 2 mM of bromouridine triphosphate (BrUTP)
was transfected into cells at 4 °C for 15 min using FuGENE 6
transfection reagent according to the manufacturer's instructions
(Roche Molecular Biochemicals, IN). The cells were washed with
phosphate-buffered saline (PBS) twice and cultured at 37 °C for
different incubation durations with DMEM supplemented with 10%
FBS. After incubation, cells were washed twice with PBS and
subsequently ﬁxed by 4% formaldehyde for 1 h at 4 °C. For
permeabilization, the cells were treated with 0.1% Triton X-100 (TX-
100) (Sigma-Aldrich, St. Louis, MO) in PBS supplemented with 1% FBS
for 30 min at room temperature. Primary antibodies were diluted in
PBS containing 1% bovine serum albumin (BSA) and incubated with
cells for 1 h at room temperature. After three washes in PBS, the cells
were incubated with ﬂuorescein isothiocyanate (FITC)-conjugated or
Rhodamine-conjugated secondary antibodies diluted at a 1:100 with
PBS containing 5% BSA for 1 h at room temperature. The cells were
then washed three times in PBS and mounted in Vectashield (Vector
Laboratories, Burlingame, CA).
Membrane ﬂotation, detergent solubilization assay
The membrane ﬂotation assay was performed as previously
described (Mizutani et al., 2000). Brieﬂy, cells were ﬁrst lysed in
1 ml of hypotonic buffer [10 mM Tris–HCV (pH 7.5), 10 mM KCl, 5 mM
MgCl2] and passed through a 25-gauge needle 20 times. Nuclei and
unbroken cells were removed by centrifugation at 1000 g for 5 min in
microcentrifuge at 4 °C. Cell lysates were then mixed with 3 ml of 72%
sucrose in low-salt buffer [LSB, comprising 50 mM Tris–HCl (pH 7.5),
25 mMKCl, and 5 mMMgCl2] and overlaid with 4ml of 55% sucrose in
LSB, followed by 1.5ml of 10% sucrose in LSB. The sucrose gradient was
centrifuged at 38,000 rpm in a Beckman SW41 Ti rotor for 14 h for 4 °C.
After centrifugation, 1-ml fractions were taken from the top of the
gradient, and each was added 1.7 ml of LSB to dilute sucrose and
concentrated by being passed through a Centricon YM-30 ﬁlter unit
(Millipore, Bedford, MA). One half of each sucrose gradient fraction
was separated by 12% SDS-PAGE and transferred to nitrocellulose
membrane. After blocking, the membrane was incubated with the
primary antibody for 1 h at 37 °C, followed by the appropriate species-
speciﬁc horseradish peroxidase conjugate, for an additional 1 h at
37 °C. Bound antibody was detected by the ECL-plus system
(Amersham, Piscataway, NJ).Transfection of siRNAs and HCV full-length RNA
The siRNAs against SYCRIP are 19-nt sequences located at nt
189–107 and nt140–1438, respectively, of SYNCRIP open reading
frame (ORF) and were synthesized by Integrated DNA Technologies,
Inc. (Coralville, IW). siRNAs were designed to target two different sites
of the human SYNCRIP gene (5′-CUAUCGUGGUGGAUAUGAAGATT-3′,
and 5′-AGACAGUGAUCUCUCUCAUGUTT-3′) chosen with the siRNA
target ﬁnder software from Ambion (http://www.ambion.com/
techlib/misc/siRNA_ﬁnder.html) (Choi, Mizutani, and Lai, 2004b).
Replicon or Huh7 cells were grown in 10% FBS-DMEM without
antibiotics. For transfection, cells were plated to a density of 105 cells
per well in a 24-well plate on day 1. Three microliters of a 20-μM stock
of siRNA duplex was mixed with 47 μl of Opti-MEM (Invitrogen, CA)
on day 2. In a separate tube, 3 μl of Lipofectamine 2000 (Invitrogen,
CA) was resuspended in 12 μl of Opti-MEM, followed by incubation at
RT for 7min. The twomixtures were combined and allowed to sit at RT
for 25 min. After the incubation, 35 μl of Opti-MEMwas added and the
100 μl mixture was directly added to the well containing 500 μl of
growth medium. On day 3, cells were trypsinized and split into a well
of the 12-well plate. On day 4, cells were re-transfected using 6 μl of
siRNAwith 6 μl of Lipofectamine 2000. On day 5, cells were harvested
either for Western blot analysis or for RNA isolation.
pHCV-1bhyb, which contains a full-length HCV RNA hybrid
sequence of genotype 1a and 1b under the control of T7 polymerase
promoter, has been described previously (Choi et al., 2004a). Full-
length HCV RNA was in vitro transcribed through T7 promoter to
obtain a positive-sense HCV RNA of about 9.6 kb. HCV full-length RNA
was then transfected into cells 1 day after siRNA re-transfection with
Mirus Trans-IT mRNA transfection reagents (Mirus Bio, WI). Brieﬂy,
1 μl of Booster reagent and 1 μl of Trans-IT reagent were added into
100 μl OPTI-MEM sequentially, followed by 1.5 μg of in vitro
transcribed HCV RNA. The mixture was incubated for 3 min at RT
and added into each well of a 12-well plate containing 1 ml of fresh
DMEM supplemented with 10% FBS. Cellular RNA was isolated from
each well at 0 to 4 days after HCV RNA transfection.Cell-free replication assay and immunodepletion experiment
Cell lysate of replicon or control Huh7 cells were prepared by a
modiﬁed protocol (Ali, Tardif, and Siddiqui, 2002). The cells grown in
100-mm-diameter dishes were washed with cold washing buffer
(150mM sucrose, 30mMHEPES [pH 7.4], 33mMammonium chloride,
7 mM KCl, 4.5 mM magnesium acetate), followed by treatment with
lysolecithin buffer (250 μg/ml of washing buffer) for 2 min. Three
milliliters of washing buffer were added to each culture plate. The
buffer was removed by aspiration. The cells were collected by scraping
in 120 μl of incomplete replication buffer (100 mM HEPES [pH 7.4];
50 mM ammonium chloride; 7 mM potassium chloride; 1 mM
spermidine; 1 mM [each] ATP, GTP, and UTP; 10 μM CTP), transferred
to a new tube, and lysed gently by pipetting 15 times. The cell
suspension was centrifuged at 1600 rpm in a microcentrifuge for
5 min at 4 °C.
For immunodepletion experiment, 40 μl of cytoplasmic fraction
(supernatant) obtained as above was treated with 1% Nonidet P-40
(NP-40) (Boehringer Mannheim, Quebec, Canada) at 4 °C for 1 h and
incubated with 0.1 μg or 1.0 μg of the indicated antibody with an
adjusted amount of PBS at 4 °C for 4 h with rotation. After incubation,
sample was incubated with 32P-CTP (30 μCi; 800 Ci/mmol), 10 μg of
actinomycin D per ml, and 800 U of RNase inhibitor per ml (Promega
Corporation, Wis.) for 3 h at 30 °C. Extraction of RNA from the total
mixture was performed with the TRI Regent (Molecular Research
Center, Inc., Cincinnati, OH). The RNA were precipitated and eluted in
10 μl of RNase-free water. The replication products were analyzed by
gel electrophoresis on 1% formaldehyde agarose gel.
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